JS Biosciences Co., Ltd.
Pioneering Cell Culture Media Supply in Apac

JS Biosciences Co., Ltd. serves as a world-class leader in cell culture technology and product innovation, acting as a trusted supplier for the biological and biopharmaceutical industries.

JSBio’s incepetion stems from Dr. Shun Luo’s strategic return to Asia following an illustrious 20-year tenure in the United States, where he actively contributed to groundbreaking pharmaceutical advancements and amassed extensive expertise in cell culture media technology. Dr. Luo foresaw that the role of cell culture media intensifies significantly after commercialization, becoming a cornerstone for sustaining premium product quality and rigid cost containment of biologics.

Dr. Luo recognized that three global players dominated the serum-free cell culture media market in the region. Dr. Luo promptly identified the necessity for establishing a company specializing in R&D, production, and sales of serum-free cell culture media.

Presently, JSBio’s capabilities in cell culture media formulation development and large-scale manufacturing have gained widespread recognition among numerous biopharmaceutical companies in Asia. The company has developed a vast array of customized media products suitable for batch, fed-batch, and perfusion culture processes. JSBio possesses an annual large-scale dry powder production capacity exceeding thousands of tons, underpinned by advanced pin milling technology, automated and intelligent production systems, precise impurity control measures, and a rigorous raw material supply chain management.

As stated by Dr. Luo, Chairman and President of JSBio, “The protein expression levels achieved by the customized cell culture media we develop for our clients significantly surpass and outstrip their expectations.”

JSBio delivers superior cell culture media formulations and development services. Serum-free cell culture media can notably improve consistency and efficacy, minimize contamination risks, and simplify downstream processes. With proprietary technology, JSBio facilitates suspension adaptation of adherent cells, enabling most suspension cell lines to grow in serum-free environments.

Offering Superlative Media Formulations and Development Services

Customers leverage JSBio’s media formulations and development services to meet the demanding requirements for high yields and quality during the commercial phase. These services offer tailor-made media formulations for large-scale production and procurement. JSBio customizes cell culture media to fit clients’ specific project needs, providing bespoke media and supplements for batch, fed-batch, and perfusion applications. This ensures maximum product yield and quality for various cell lines, including CHO, HEK293, Vero, Sf9/ SF21, MDCK, etc., helping clients achieve superior platform performance, dependable product supply, and cost efficiency while mitigating supply chain risks.

Delivering Customer-Focused Cell Culture Process and Technical Services

With a ‘customer-focused’ approach, JSBio prioritizes prompt, round-the-clock responsiveness and collaborations to ensure customer success. In cell culture process development, the company provides full services in the JSBio laboratory, and semi-contracted services in clients’ laboratories. Other services include customized media formulation, formula components, media form, packaging specifications, and inspection items.

JSBio currently operates in Haimen, Shanghai, Lanzhou (China), South Korea, and the U.S. to meet the global demands for biologic drugs. Its manufacturing facilities are equipped with state-of-the-art production equipment, and the company adheres to GMP compliance to ensure world-class standards. The company has implemented standardized and harmonized processes, raw materials, and qualifications across all sites, providing customers with manufacturing flexibility.

The capacity to produce large quantities of media gives JSBio a competitive edge in serving the rapidly growing biopharmaceutical markets. By incorporating customized design, JSBio has achieved an advanced production process. For example, the company’s production line incorporates built-in temperature regulation monitoring and explosion prevention mechanisms, alongside humidity and oxidation control systems. These features are crucial to processing a broader spectrum of media with enhanced precision and safety. Also, control over residence time in the mill ensures particles are reduced to the desired size while maintaining optimal efficiency.

The protein expression levels achieved by the customized cell culture media we develop for our clients significantly surpass and outstrip their expectations

For example, JSBio’s R&D team collaborated with a Covid-19 vaccine company in 2021. By optimizing technologies and processes, the collaboration resulted in a 17-fold increase in vaccine production, significantly accelerating commercial processes.

Establishing Long-Term Partnerships

By offering different types of media, JSBio demonstrates flexibility in meeting client preferences and process requirements. For example, when meeting scientific research clients who require a small quantity of pre-configured liquid culture medium, the company provides liquid culture medium products within a quick turnaround time of 2-3 weeks.

On the other hand, industrial clients typically have a high demand for large quantities of culture media, often exceeding 2000L. To accommodate their transportation and storage needs, JSBio rapidly produces dry powder media and arranges corresponding logistics for efficient delivery.

“We pride ourselves on our industry-leading lead time of 30-45 days, ensuring a seamless transition from small to large scales with our flexible dry powder capacity. Our lot-to-lot consistency guarantees reliable and consistent product quality,” says Dr. Luo.

JSBio adheres to a compliance system that meets customer regulatory expectations. This helps to decrease the customer’s burden on upstream processes for clients. Long-term partnerships with over 500 biopharmaceutical companies and research institutes have also contributed to the successful launch of hundreds of antibody and vaccine products.

“As the industry evolves, we stand to lead the charge in innovative cell culture solutions, setting new benchmarks for excellence and reliability,” says Dr. Luo.